Avid Bioservices Inc (CDMO)

[pphmtoolong]

Sunrise:
Experimental: bavituximab plus docetaxel
Six 21-day cycles of docetaxel plus weekly bavituximab. Patients who have not experienced disease progression will continue to receive bavituximab weekly until progression.

So, at this point there are close to 300 Bavi-arm patients who have received or are receiving weekly Bavi treatment. I hope many of these patients have not progressed.

Just a few more months to learn if Bavi is the real deal in this deadly disease. I guestimate early April will give us our first look-in. The second two to three months later.

Waiting is the hardest part, but we longs ought to be used to it.

Paul